Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Lumito

0.02 SEK

Less than 1K followers

LUMITO

Nordic SME

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+6.67 %
-57.89 %
-80.41 %
-92.75 %
-92.51 %
-90.11 %
-96.88 %
-98.85 %
-96.72 %

Lumito is a Swedish company that develops and markets systems for tissue and biomarker analysis in digital pathology, built on upconverting nanoparticle technology. The company targets healthcare facilities, research and the pharmaceutical sector. The company was formed in 2010 as a spinoff from a research group at Lund University's Department of Atomic Physics and Laser Center. Lumito is headquartered in Lund.

Read more
Market cap
27.53M SEK
Turnover
-
Revenue
100K
EBIT %
-38,300 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20/2
2026

Annual report '25

7/5
2026

General meeting '26

7/5
2026

Interim report Q1'26

All
Press releases
3rd party
ShowingAll content types
Regulatory press release20 hours ago

Lumitos teknologi möjliggör kvantifiering av celler som förekommer i mycket låg mängd

Lumito
Regulatory press release20 hours ago

Lumito’s technology enables quantification of low abundant cells

Lumito
Regulatory press release12/12/2025, 8:00 AM

Lumito strengthens its international presence and participates in Digital Pathology & AI Congress Europe

Lumito

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release12/12/2025, 8:00 AM

Lumito stärker sin internationella närvaro och deltar vid Digital Pathology & AI Congress Europe

Lumito
Regulatory press release12/11/2025, 9:30 AM

Lumito förnyar sin kvalitetscertifiering, ISO 13485:2016

Lumito
Regulatory press release12/11/2025, 9:30 AM

Lumito renews its quality certification, ISO 13485:2016

Lumito
Regulatory press release12/5/2025, 1:15 PM

Valberedning i Lumito inför årsstämma 2026 utsedd

Lumito
Regulatory press release12/5/2025, 1:15 PM

Nomination Committee for Lumito appointed ahead of the 2026 Annual General Meeting

Lumito
Regulatory press release12/2/2025, 7:30 AM

Lumito rekryterar Chief Business Officer för att accelerera kommersiell tillväxt

Lumito
Regulatory press release12/2/2025, 7:30 AM

Lumito Appoints Chief Business Officer to accelerate commercial growth

Lumito
Regulatory press release11/27/2025, 7:30 AM

Lumito AB publicerar kvartalsrapport 3, 2025

Lumito
Regulatory press release11/27/2025, 7:30 AM

Lumito AB publishes interim report for the third quarter of 2025

Lumito
Regulatory press release11/25/2025, 9:00 AM

Inbjudan till webbinarium i samband med Lumito AB:s delårsrapport Q3 2025

Lumito
Regulatory press release11/25/2025, 9:00 AM

Invitation to webinar in connection with Lumito AB’s Q3 2025 Interim Report

Lumito
Regulatory press release11/21/2025, 8:45 AM

Lumito beviljas affärsutvecklingscheck om 250 KSEK från Region Skåne

Lumito
Regulatory press release11/21/2025, 8:45 AM

Lumito granted SEK 250,000 business development grant from Region Skåne

Lumito
Regulatory press release11/19/2025, 3:45 PM

Conversion of paid subscribed units (BTUs) and first day of trading in warrants of series TO7

Lumito
Regulatory press release11/19/2025, 3:45 PM

Omvandling av betalda tecknade units (BTU) och första dag för handel med teckningsoptioner av serie TO7

Lumito
Press release11/19/2025, 6:47 AM

BioStock: Video från Lumitos presentation vid BioStock Life Science Summit 2025

Lumito
Press release11/19/2025, 6:47 AM

BioStock: Video from Lumito's presentation at BioStock Life Science Summit 2025

Lumito
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.